{
  "docId": "019de516-48a5-7631-970d-a6192a59c040",
  "docSlug": "5b4cac48a3342d745accb48141e027b4",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 39 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 39,
  "prevPage": 34,
  "nextPage": 36,
  "slideType": "revenue_buildup",
  "function": "decompose_segments",
  "density": "dense",
  "nDataPoints": 100,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-48a5-7631-970d-a6192a59c040/35",
  "deckHref": "/decks/019de516-48a5-7631-970d-a6192a59c040",
  "deckJsonHref": "/decks/019de516-48a5-7631-970d-a6192a59c040.json",
  "deckAnchorHref": "/decks/019de516-48a5-7631-970d-a6192a59c040#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.099,
        "w": 0.737,
        "x": 0.183,
        "y": 0.877
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and Non-GAAP Appendix for further information on non-GAAP measures and ratios.\n2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision\nCare segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements\nwas not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.\n3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency\nexchange rates during the comparable prior period.\n4. As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their respective categories. Prior period\npresentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis.\n5. Contact Lens Revenue Impact of distribution facility disruptions is approximately $15M.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5532c703-27d4-46ed-81f5-05e1db3b9ab4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.71,
        "w": 0.81,
        "x": 0.109,
        "y": 0.149
      },
      "kind": "table",
      "text": "Calculation of Constant Currency Revenue for the Three Months Ended\nJune 30, 2023\nJune 30, 2022\nChange in\nReported Revenue\nChange in\nConstant Currency Revenue¹\nConstant\nCurrency\nRevenue as\nReported\nChanges in\nExchange Rates³\nRevenue (Non-\nGAAP)¹\nRevenue as\nReported\nAmount\nPct.\nAmount\nPct.\nContact Lens\n215\n6\n221\n213\n2\n1%\n8\n4%\nConsumer²\n431\n9\n440\n375\n56\n15%\n65\n17%\nSurgical Consumables\n102\n1\n103\n93\n9\n10%\n10\n11%\nSurgical Implantables\n47\n47\n49\n(2)\n-4%\n(2)\n-4%\nSurgical Equipment\n46\n46\n42\n4\n10%\n4\n10%\nLumify\n43\n43\n35\n8\n23%\n8\n23%\nOcuvite + PreserVision\n104\n1\n105\n94\n10\n11%\n11\n12%\nArtelac\n36\n36\n29\n7\n24%\n7\n24%\nContact Lens (excluding impact of\ndistribution facility disruptions)\n230\n6\n236\n213\n17\n8%\n23\n10%\nPremium IOLS\n11\n1\n12\n9\n2\n22%\n3\n33%\nInternational Pharmaceuticals2\n82\n2\n84\n70\n12\n17%\n14\n20%\nVyzulta\n15\n15\n12\n3\n25%\n3\n25%",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "531143a2-45af-4b12-b5aa-0f6964d6ec3a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 14,
      "beatId": "83fb7e88-f765-459a-865d-12d458331d10",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The company outlines its plans for future growth and provides additional information.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}